References

Filters: Yattoo-2018. is   [Clear All Filters]
P
Pianko S, Flamm SL, Shiffman ML, et al. Sofosbuvir plus velpatasvir combination therapy for treatment-experienced patients with genotype 1 or 3 hepatitis C virus infection: a randomized trial. Kumar S, Strasser SI, Dore GJ, et al., eds. Ann Intern Med. 2015;163(11):809-817.
Picciotto FP, Tritto G, Lanza AG, et al. Sustained virological response to antiviral therapy reduces mortality in HCV reinfection after liver transplantation. J Hepatol. 2007;46(3):459-465.
Pineda JA, Romero-Gomez M, Díaz-García F, et al. HIV coinfection shortens the survival of patients with hepatitis C virus-related decompensated cirrhosis. Giron-Gonzalez JA, Montero JL, Torre-Cisneros J, et al., eds. Hepatology. 2005;41(4):779-789.
Platt L, Minozzi S, Reed J, et al. Needle syringe programmes and opioid substitution therapy for preventing hepatitis C transmission in people who inject drugs. Cochrane Database of Systematic Reviews. 2017;9(9). doi:10.1002/14651858.CD012021.pub2.
Pokorska-Spiewak M, Kowalik-Mikolajewska B, Aniszewska M, Pluta M, Marczynska M. Clinical usefulness of new noninvasive serum biomarkers for the assessment of liver fibrosis and steatosis in children with chronic hepatitis C. Clin Exp Hepatol. 2017;3:198-202.
Pol S, Bourliere M, Lucier S, et al. Safety and efficacy of daclatasvir-sofosbuvir in HCV genotype 1-mono-infected patients. Hézode C, Dorival C, Larrey D, et al., eds. J Hepatol. 2017;66(1):39-47.
Poordad F, Pol S, Asatryan A, et al. MAGELLAN-1, part 2: glecaprevir and pibrentasvir for 12 or 16 weeks in patients with chronic HCV genotype 1 or 4 and prior direct-acting antiviral treatment failure. Buti M, Shaw DR, Hezode C, et al., eds. Gastroenterology. 2017;152(5):S1057.
Poordad F, Hézode C, Trinh R, et al. ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. Kowdley KV, Zeuzem S, Agarwal K, et al., eds. N Engl J Med. 2014;370(21):1973-1982.
Poordad F, Felizarta F, Asatryan A, et al. Glecaprevir and pibrentasvir for 12 weeks for hepatitis C virus genotype 1 infection and prior direct-acting antiviral treatment. Sulkowski MS, Reindollar RW, Landis CS, et al., eds. Hepatology. 2017;66(2):389-397.
Poordad F, Schiff ER, Vierling JM, et al. Daclatasvir with sofosbuvir and ribavirin for hepatitis C virus infection with advanced cirrhosis or post-liver transplantation recurrence. Hepatology. 2016;63(5):1493 - 1505. doi:10.1002/hep.28446.
Poordad F, Pol S, Asatryan A, et al. Glecaprevir/pibrentasvir in patients with hepatitis C virus genotype 1 or 4 and past direct-acting antiviral treatment failure. Hepatology. 2018;67(4):1260.
Post JJ, Arain A, Lloyd AR. Enhancing assessment and treatment of hepatitis C in the custodial setting. Clin Infect Dis. 2013;57(Suppl 2):S70-S74.
Potluri VS, Goldberg DS, Mohan S, et al. National trends in utilization and 1-year outcomes with transplantation of HCV-viremic kidneys. J Am Soc Nephrol. 2019;30:1939-1951.
Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet. 1997;349(9055):825-832.
Poynard T, Ratziu V, Charlotte F, Goodman Z, McHutchison JG, Albrecht J. Rates and risk factors of liver fibrosis progression in patients with chronic hepatitis C. J Hepatol. 2001;34(5):730-739.
Poynard T, McHutchison JG, Manns M, et al. Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. Gastroenterology. 2002;122(5):1303-1313.
Poynard T, Cacoub P, Ratziu V, et al. Fatigue in patients with chronic hepatitis C. J Viral Hepat. 2002;9(4):295-303.
Pradat P, Alberti A, Poynard T, et al. Predictive value of ALT levels for histologic findings in chronic hepatitis C: a European collaborative study. Hepatology. 2002;36(4 Pt 1):973-977.
Prasad MR. Hepatitis C virus screening in pregnancy: is it time to change our practice?. Obstet Gynecol. 2016;128(2):229-230.
Prenner SB, VanWagner LB, Flamm SL, Salem R, Lewandowski RJ, Kulik L. Hepatocellular carcinoma decreases the chance of successful hepatitis C virus therapy with direct-acting antivirals. J Hepatol. 2017;66(6):1173-1181.
Top